Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYRNUO vs DOSTINEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
(E)-2-(((2-(6,7-dimethoxyquinazolin-4-ylamino)phenyl)thio)methyl)-4-methyl-2H-pyrazolo[1,5-a]pyrazin-3(5H)-one is a selective inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4. It binds to the ATP-binding site of FGFR kinases, blocking downstream signaling pathways, including RAS-MAPK-ERK and PI3K-AKT, thereby inhibiting tumor cell proliferation and angiogenesis.
Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by binding to D2 receptors on lactotroph cells in the anterior pituitary.
Treatment of adult patients with previously treated, unresectable locally advanced or metastatic urothelial carcinoma (UC) with FGFR3 genetic alterations,Treatment of adult patients with unresectable locally advanced or metastatic cholangiocarcinoma (CCA) with FGFR2 gene fusions or other rearrangements
Treatment of hyperprolactinemic disorders (e.g., amenorrhea, galactorrhea, infertility),Prolactin-secreting pituitary adenomas (prolactinomas),Off-label: Reduction of breast engorgement postpartum (non-FDA)
100 mg orally once daily
0.25 mg orally twice weekly, with a minimum of 2 days between doses; may increase by 0.25 mg twice weekly every 4 weeks up to a maximum of 1 mg twice weekly.
Terminal elimination half-life is 12-15 hours in adults with normal renal function, supporting twice-daily dosing.
The terminal elimination half-life is 63–69 hours in healthy volunteers and 79–115 hours in patients with hyperprolactinemia, allowing once- or twice-weekly dosing. The long half-life reflects slow dissociation from D2 receptors and enterohepatic recirculation.
Primarily metabolized by CYP2C9 and CYP3A4; minor contributions from CYP2C19 and CYP2D6. Forms active metabolites M1 (desmethyl) and M2 (N-oxide).
Extensively metabolized in the liver, primarily via hydrolysis of the acylurea bond; CYP3A4 is involved in minor hydroxylation pathways.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30% (including metabolites), with the remainder eliminated via minor metabolic pathways.
Cabergoline is extensively metabolized in the liver, primarily via CYP3A4. Elimination is predominantly fecal (60%) and renal (20%) as metabolites, with <4% as unchanged drug. Biliary excretion contributes to fecal elimination.
98% bound primarily to albumin.
Approximately 41–42% bound to plasma proteins, primarily albumin.
0.3-0.4 L/kg, indicating distribution into total body water with limited tissue binding.
The apparent volume of distribution is approximately 150–200 L, indicating extensive tissue distribution. In L/kg (assuming 70 kg), Vd ≈ 2.1–2.9 L/kg. This large Vd suggests sequestration in tissues, including the pituitary.
Oral: 85% (fasting); 60% with high-fat meal (reduced absorption).
Oral bioavailability is approximately 50–60% due to first-pass metabolism. Food does not significantly affect absorption.
GFR ≥60 m L/min: No adjustment. GFR 30-59: 50 mg once daily. GFR <30: Not recommended.
No specific recommendations; use caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
Child-Pugh A: No adjustment. Child-Pugh B: 50 mg once daily. Child-Pugh C: Not recommended.
No specific recommendations; use caution in severe hepatic impairment (Child-Pugh class C) due to reduced clearance.
Not established for patients under 18 years.
Safety and effectiveness in pediatric patients have not been established; not recommended.
No specific dose adjustment; monitor renal function and consider age-related decline.
No specific dose adjustment; monitor for orthostatic hypotension and neuropsychiatric effects.
None
None.
Retinal pigment epithelial detachment (RPED) and other visual disturbances: conduct ophthalmic examinations prior to and during treatment,Hyperphosphatemia: monitor serum phosphate levels and manage with phosphate-lowering therapy or dose modification,Non-healing corneal ulcers: requires ophthalmologic evaluation,Embryo-fetal toxicity: can cause fetal harm; advise effective contraception
Risk of valvulopathy and cardiac fibrosis with long-term use, especially at high cumulative doses,May cause hypotension, syncope, or orthostatic hypotension,Monitor for pleural effusion, pulmonary fibrosis, and pericarditis,Impulse control disorders (e.g., pathological gambling, hypersexuality),Somnolence and sudden sleep onset; caution when driving
Concurrent use with strong CYP2C9 or CYP3A4 inducers,Pregnancy and lactation
Uncontrolled hypertension,Preeclampsia or eclampsia,Known hypersensitivity to ergot derivatives,History of pulmonary, pericardial, or retroperitoneal fibrotic disorders
No specific food interactions. Grapefruit juice does not significantly affect HYRNUO metabolism. Maintain consistent vitamin K intake if on warfarin; not applicable to HYRNUO. Alcohol may increase bleeding risk; advise moderation.
No specific food restrictions. However, high-fat meals may increase absorption, but no dose adjustment is required. Avoid alcohol due to increased risk of dizziness and gastrointestinal upset. Grapefruit juice may inhibit CYP3A4 and increase cabergoline levels; consider avoiding large quantities.
HYRNUO is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies and limited human data. First trimester exposure is associated with major congenital malformations including neural tube defects and cardiovascular anomalies. Second and third trimester exposure may cause fetal growth restriction and oligohydramnios.
Category B: Animal studies (rats, rabbits) at doses up to 2.5 mg/kg/day showed no teratogenic effects but embryotoxicity at high doses. No adequate human studies. Post-marketing reports of spontaneous abortion and congenital anomalies (limb defects, cardiac) but causal relationship unestablished. Avoid in pregnancy unless benefit outweighs risk. Use only after excluding pregnancy and using effective contraception during treatment until 1 month after discontinuation.
No data available on excretion into breast milk or effects on the breastfed infant. M/P ratio unknown. Due to potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose.
Excreted into human milk. Peak milk concentration ~0.15-0.25 ng/m L after 0.25 mg oral dose. M/P ratio unknown. Due to potential for suppression of lactation and unknown infant effects, contraindicated in breastfeeding women. Discontinue nursing or avoid drug.
No established safe dose in pregnancy. Drug should not be used. If accidental exposure occurs, pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may require dose adjustment, but no specific recommendations exist.
No specific dose adjustments recommended due to contraindication in pregnancy. If inadvertently exposed, discontinue immediately. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may reduce efficacy, but no formal dose adjustment studies exist. Use is not advised.
HYRNUO is a novel oral anticoagulant with high specificity for factor Xa. Monitor renal function prior to initiation and periodically; adjust dose if Cr Cl <30 m L/min. No routine coagulation monitoring required. Reversal agent andexanet alfa is available for life-threatening bleeding. Avoid in patients with mechanical heart valves or moderate-to-severe mitral stenosis. Caution with dual antiplatelet therapy due to increased bleeding risk.
Dostinex (cabergoline) is a long-acting dopamine D2 receptor agonist used primarily for hyperprolactinemia. Its half-life of 63-69 hours allows once or twice weekly dosing. Monitor for valvular heart disease with echocardiography before and during therapy due to risk of fibrotic reactions, especially at high doses used in Parkinson's disease. Avoid concurrent use with CYP3A4 inhibitors (e.g., macrolides, azole antifungals) that can increase cabergoline levels. Titrate dose gradually to minimize orthostatic hypotension and gastrointestinal side effects.
Take HYRNUO exactly as prescribed, usually once daily with or without food.,Do not skip doses; if a dose is missed, take it as soon as remembered on the same day. Do not double the next dose.,Inform all healthcare providers that you are taking HYRNUO, especially before surgery or dental procedures.,Watch for signs of bleeding: unusual bruising, prolonged bleeding from cuts, pink/brown urine, red/black stools, coughing up blood, or vomiting blood.,Avoid aspirin, NSAIDs, or other blood thinners unless prescribed by your doctor.,Keep a list of all medications and supplements you take, as some may interact with HYRNUO.,Store at room temperature away from moisture and heat. Do not stop taking without consulting your doctor.
Take exactly as prescribed, typically once or twice per week; do not double doses if missed. Take with food if nausea occurs. Avoid alcohol as it may increase side effects. Report any shortness of breath, cough, chest pain, or swelling of extremities immediately (signs of valvulopathy). Do not drive or operate machinery until you know how the medication affects you, as it may cause dizziness or drowsiness. Women who may become pregnant should use effective contraception; stop cabergoline if pregnancy is confirmed. Inform all healthcare providers about this medication, including before any surgery or dental procedures. Keep out of reach of children and store at room temperature.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYRNUO vs DOSTINEX, answered by our medical review team.
HYRNUO is a Dopamine Agonist (Antiparkinsonian) that works by (E)-2-(((2-(6,7-dimethoxyquinazolin-4-ylamino)phenyl)thio)methyl)-4-methyl-2H-pyrazolo[1,5-a]pyrazin-3(5H)-one is a selective inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4. It binds to the ATP-binding site of FGFR kinases, blocking downstream signaling pathways, including RAS-MAPK-ERK and PI3K-AKT, thereby inhibiting tumor cell proliferation and angiogenesis.. DOSTINEX is a Dopamine Agonist that works by Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by binding to D2 receptors on lactotroph cells in the anterior pituitary.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYRNUO and DOSTINEX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYRNUO is: 100 mg orally once daily. The standard adult dose of DOSTINEX is: 0.25 mg orally twice weekly, with a minimum of 2 days between doses; may increase by 0.25 mg twice weekly every 4 weeks up to a maximum of 1 mg twice weekly.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYRNUO and DOSTINEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYRNUO is classified as Category C. HYRNUO is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies and limited human data. First trimester exposure is associated with major congenital mal. DOSTINEX is classified as Category C. Category B: Animal studies (rats, rabbits) at doses up to 2.5 mg/kg/day showed no teratogenic effects but embryotoxicity at high doses. No adequate human studies. Post-marketing re. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.